Cantata Bio
Private Company
Total funding raised: $30.2M
Overview
Cantata Bio (Dovetail Genomics) is a private, revenue-generating platform company focused on advanced genomics. Its core innovation is the Dovetail® LinkPrep™ technology, a linked-read assay that uses proximity ligation to preserve spatial DNA relationships, overcoming the limitations of short-read sequencing. This platform enables applications across genome assembly, 3D genomics, and genetic variation analysis, positioning the company as a key enabler for complex genomic research in academia and biopharma. The company operates as part of the EdenRoc Sciences ecosystem and distributes its products globally.
Technology Platform
Dovetail® LinkPrep™ linked-read technology using proximity ligation to capture long-range genomic and 3D chromatin interaction information from short-read sequencing data.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Competes directly with long-read sequencing platforms (PacBio, Oxford Nanopore) for genome assembly and variant detection. Faces competition in 3D genomics from dedicated Hi-C service providers and kit manufacturers (e.g., Arima Genomics, Phase Genomics). Also competes within the broader NGS enrichment and sample prep market dominated by large players like Illumina.